Shares of drug firm Strides Shasun ended with over 4 per cent gains today after the US health regulator completed a successful inspection of the company’s oral dosage facility at Bengaluru without any adverse observations.
After surging 6.77 per cent to Rs 1,205 on BSE during the day, the stock finally ended at Rs 1,176.50, up 4.25 per cent.
At NSE, shares of the company rose 4.27 per cent to close at Rs 1,177.10.
In terms of volume, 1.20 lakh shares of the company were traded at BSE and more than 6 lakh shares changed hands at NSE during the day.
The United States Food and Drug Administration (USFDA) has completed the inspection of the company’s oral dosage facility at Bengaluru with ‘Zero 483s’, Strides Shasun had yesterday said in a filing to BSE.
With the recently-closed Establishment Inspection Report (EIR), the entire facility is now USFDA-compliant, it added.
“The audit was carried out related to a product filed from the new semi solids block from where the company has made a series of filings,” Strides Shasun said.
The Bengaluru facility manufactures oral dosage forms, including tablets, capsules, ointments and liquids.
The plant supports current and future submissions for the US market, Strides Shasun said.
No comments:
Post a Comment